புதுப்பிப்புகள்
டீல்
டீல் மதிப்பு—
டீல் vs வணிகம்Acquisition adds ₹9.0–9.5 Cr incremental revenue vs ₹44 Cr TTM revenue (~21% uplift)
செயல்படுத்தும் காலம்1.0 ஆண்டு
அடிப்படை தரம்C
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)21.0% / 21.0%
EPS உயர்வு65.0%
அப்சைடு பேஸ் / புல் / பேர்35.0% / 75.0% / -30.0%
கால எல்லை12-24 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம் (04 ஆக. 2026)₹19.75
சமீபத்திய முடிவு விலை (11 நவ. 2026)₹24.7
தொடங்கியதிலிருந்து வருமானம்+25.1%
α vs Smallcap 250+26.6%
α vs சொந்தத் துறை+31.5% (ஹெல்த்கேர் இடைநிலை -4.9%, 55 முதிர்ந்த தேர்வுகளின் அடிப்படையில்)
நேர்மறைகள்
- Q1 FY27 revenue surge of 60% YoY to ₹8.13 Cr with pre-tax/depreciation margin improving from 11.1% to 18.8%.
- Inorganic expansion via Anand Hospital acquisition adding ₹9-9.5 Cr top-line (21% increase over TTM revenue).
- Bed capacity expansion from 130 to 330 beds, with potential trajectory to 430 beds.
- Specialty addition with CTVS department at Jupiter Hospital and new IVF centre at Karelibaug.
- Low valuation base at 0.8x P/B and ₹41 Cr market cap.
அபாயங்கள்
- Depressed ROCE (3.6%) and volatile operating margins historically (OPM dropped from ~30% in FY23 to 8.9% TTM).
- High working capital risk due to dependency on PMJAY government scheme reimbursement delays.
- 100% regional concentration in the Gujarat healthcare market.
- Debt burden of ₹21 Cr against TTM PAT of ₹1 Cr (D/E of 0.41x).
முழு AI சுருக்கம்
Aatmaj Health (AATMAJ) — Catalyst & Growth Potential Analysis
1. Catalyst Assessment & Ramp-Aware Impact Math
- Announcement Summary: On 2026-08-03, Aatmaj reported Q1 FY27 revenue of ₹8.13 Cr (+60% YoY) and pre-tax/depreciation profit of ₹1.52 Cr (+170% YoY). The company announced the acquisition of Anand Hospital in Vadodara, expected to contribute ₹9.0–9.5 Cr in FY27 revenue.
- Revenue Impact Math:
- Baseline TTM Revenue = ₹44.0 Cr.
- Incremental revenue from Anand Hospital = ~₹9.25 Cr (midpoint).
- Steady-state annual revenue uplift = 9.25 / 44.0 = +21%.
- Year 1 revenue expected to reach ~₹53.25 Cr.
- Margin & EPS Impact Math:
- Operating margin in Q1 FY27 reached 18.76% (pre-tax/depreciation). Assuming steady-state net margin of 5.5–6.5% on incremental hospital revenues, additional PAT = ₹0.55–0.60 Cr.
- Baseline TTM PAT = ₹1.0 Cr (EPS ₹0.61).
- Incremental PAT increases total net profit to ~₹1.60–1.65 Cr, representing a +65% EPS uplift.
2. Industry Context & Operational Feasibility
- Industry: Healthcare & Hospital Operations.
- Capital Intensity: HIGH (requires continuous outlay for hospital acquisitions, medical equipment, CTVS/IVF infrastructure).
- Execution Difficulty: Moderate to High. Integrating acquired hospitals (Anand Hospital) and scaling occupancy requires operational management, clinical talent retention, and working capital buffer.
- Expected Industry CAGR: 12%–15%.
3. அடிப்படைத் தரம் & நிதி ஆரோக்கியம்
- ROCE: 3.6% — current capital efficiency is very low due to unmonetized capex and recent hospital integrations.
- Balance Sheet: Debt of ₹21 Cr on Net Worth of ₹51 Cr (D/E 0.41x). Partial recovery of 5% old debt provides marginal relief.
- Promoter Holding: Stable at 64.33%.
- Client & Payment Concentration Risk: High reliance on government PMJAY schemes leads to extended working capital cycles and settlement delays.
4. Valuation & Re-rating Potential
- Current Price: ₹18.5 | Market Cap: ₹41 Cr | Trailing P/E: 30.3x | P/B: 0.8x.
- Peer median trailing P/E is ~69.5x, reflecting small-cap valuation discount for Aatmaj due to execution track record and low ROCE.
5. Scenario Analysis & Price Targets
- Base Case (+35% upside to ₹25.0): Anand Hospital contributes ₹9 Cr revenue in FY27. Annualized revenue reaches ₹52 Cr and PAT reaches ₹1.6 Cr. Forward P/E re-rates modestly to 25x.
- Bull Case (+75% upside to ₹32.4): Bed capacity utilization ramps quickly to 430 beds, PMJAY receivables normalize, margins improve to 8% PAT margin (PAT ~₹2.2 Cr). Market re-rates stock to 30x forward P/E.
- Bear Case (-30% downside to ₹13.0): Acquisition integration delays and PMJAY payment lock-ups strain liquidity, keeping ROCE sub-4% and compressing net profit back to <₹0.8 Cr.
6. தீர்ப்பின் காரணம்
- Verdict: POSSIBLE (Score: 45/100).
- The acquisition of Anand Hospital and strong Q1 FY27 print provide genuine top-line expansion (~21% uplift). However, low historical ROCE (3.6%), volatile net margins, and working capital risks tied to PMJAY keep the verdict at POSSIBLE rather than a high-conviction candidate.
2026-08-03 நிலவரப்படி பகுப்பாய்வு (விலை ₹18.50) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
